Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AL-034 in healthy adults
NCT03285620Phase 1Completed
- Sponsor
- Alios BioPharma
- Start
- Sep 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tq-a3334 in hepatitis B (HBV) (2 arms), sponsored by Alios BioPharma. Primary endpoints: Adverse Events, Clinically Significant Changes in Physical Examination and 8 more. Started Sep 2017; status: completed.
02
Drugs
tq-a3334
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT03285620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03285620.